You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

donafenib

Showing 1 - 16 of 16
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Nasopharyngeal Carcinoma Trial in Beijing (Donafenib)

Recruiting
  • Nasopharyngeal Carcinoma
  • Donafenib
  • Beijing, Beijing, China
    Cancer Hospital of Medical College
Nov 28, 2022

Hepatocellular Carcinoma Trial (Donafenib, TACE)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Donafenib
  • TACE
  • (no location specified)
Oct 8, 2022

Hepatocellular Carcinoma Trial (HAIC(FOLFOX), Oxaliplatin, Leucovorin)

Not yet recruiting
  • Hepatocellular Carcinoma
  • HAIC(FOLFOX)
  • +5 more
  • (no location specified)
Aug 16, 2022

Biliary Tract Adenocarcinoma Trial in Shanghai (HAIC, Gemcitabine, Oxaliplatin)

Enrolling by invitation
  • Biliary Tract Adenocarcinoma
  • HAIC
  • +4 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
May 27, 2022

Hepatocellular Carcinoma Trial (Donafenib, Sintilimab, HAIC)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Donafenib
  • +2 more
  • (no location specified)
Dec 21, 2021

Differentiated Thyroid Cancer Trial in Beijing (Donafenib, Placebo)

Terminated
  • Differentiated Thyroid Cancer
  • Donafenib
  • Placebo
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Nov 29, 2021

Hepatocellular Carcinoma Trial in Beijing (HAIC, TACE, FOLFOX)

Recruiting
  • Hepatocellular Carcinoma
  • HAIC
  • +4 more
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Jan 10, 2022

Metastatic Pancreatic Cancer Trial in Shanghai (Donafenib, S1)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Shanghai, China
    Fudan University
Nov 17, 2021

Hepatocellular Carcinoma Trial in Beijing (Donafenib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Donafenib
  • Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Dec 2, 2021

HCC, Chemo Effect Trial (Donafenib)

Not yet recruiting
  • HCC
  • Chemotherapy Effect
  • Donafenib
  • (no location specified)
Sep 16, 2021

Carcinoma, Carcinoma, Hepatocellular, Liver Tumors Trial in Guangzhou (Hepatic arterial infusion chemo, Folfox Protocol,

Not yet recruiting
  • Carcinoma
  • +8 more
  • Hepatic arterial infusion chemotherapy
  • +2 more
  • Guangzhou, Guangdong, China
    Lei Zhang
Sep 22, 2021

Advanced Solid Tumor Trial in Shanghai (Donafenib, CS1001)

Recruiting
  • Advanced Solid Tumor
  • Shanghai, Shanghai, China
    Shanghai Eastern Hospital
Jul 12, 2021

Acute Myeloid Leukemia (AML) Trial in Tianjin (Donafenib)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Donafenib
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Disease Hospital
Jun 21, 2021

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • TACE
  • +8 more
  • Quanzhou, Fujian, China
  • +3 more
Jan 29, 2023

HCC Trial in Nanjing, Chengdu (Donafenib, Sorafenib)

Completed
  • HCC
  • Nanjing, Jiangsu, China
  • +1 more
Jan 7, 2020